13 dec: Indberetning af ledende medarbejders og disses nærtståendes trans..
14 dec: Statsgældspolitikken - Strategimeddelelse 2019
13-12-2018 21:58:39

Genmab Announces Submission of Supplemental New Drug Application for Daratumumab in Front Line Multiple Myeloma in Japan

Company Announcement

  • Supplemental new drug application submitted in Japan for daratumumab in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplant

  • Submission based on data from Phase III ALCYONE study

  • Genmab to receive USD 2 million milestone payment from Janssen

Copenhagen, Denmark; December 14, 2018 –

Genmab A/S (Nasdaq Copenhagen: GEN) announced today that Janssen Pharmaceutical K.K. has submitted a supplemental new drug application (sNDA) to the Ministry of Health, Labor and Welfare (MHLW) in Japan, for the use of daratumumab (DARZALEX®) in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).  The application will receive a priority review. The submission of the application triggers a milestone payment of USD 2 million to Genmab from Janssen. In February 2018, the MHLW granted Orphan Drug Designation to DARZALEX for patients with newly diagnosed multiple myeloma. In August 2012, Genmab granted Janssen an exclusive worldwide license to develop, manufacture and commercialize daratumumab.

“We are extremely pleased that daratumumab in front line multiple myeloma has now been submitted in Japan. Should this submission be approved, it would bring an exciting new therapeutic option to Japanese multiple myeloma patients in need,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

The submission was based on data from the Phase III ALCYONE study that showed a reduction of the risk of disease progression or death by 50 percent in newly diagnosed ASCT ineligible multiple myeloma patients when daratumumab is combined with bortezomib, melphalan and prednisone. This data was presented as a Late-Breaking Abstract at the 2017 American Society of Hematology (ASH) Annual Meeting and published in The New England Journal of Medicine in December, 2017.

About the ALCYONE study

This Phase III study (NCT02195479) is a randomized, open-label, multicenter study and includes 706 newly diagnosed patients with multiple myeloma who are ineligible for ASCT. Patients were randomized to receive 9 cycles of either VMP [bortezomib (a proteasome inhibitor), melphalan (an alkylating chemotherapeutic agent) and prednisone (a corticosteroid)] combined with daratumumab, or VMP alone. In the daratumumab treatment arm, patients received 16 mg/kg of daratumumab once weekly for six weeks (cycle 1; 1 cycle = 42 days), once every three weeks from cycles 2 to 9, once every 4 weeks from cycle 9 until disease progression.  The primary endpoint of the study is progression free survival (PFS).

About multiple myeloma

Multiple myeloma is an incurable blood cancer that starts in the bone marrow and is characterized by an excess proliferation of plasma cells.1 Multiple myeloma is the third most common blood cancer in Japan, after leukemia and lymphoma.2 Approximately 8,200 new patients were projected to be diagnosed with multiple myeloma and approximately 4,200 people were projected to die from the disease in Japan in 2017.2 Globally, it was estimated that 124,225 people would be diagnosed and 87,084 would die from the disease in 2015.3  While some patients with multiple myeloma have no symptoms at all, most patients are diagnosed due to symptoms which can include bone problems, low blood counts, calcium elevation, kidney problems or infections.4 Patients who relapse after treatment with standard therapies, including proteasome inhibitors or immunomodulatory agents, have poor prognoses and few treatment options.5




DARZALEX® (daratumumab) injection for intravenous infusion is indicated in the United States  in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor (PI); and as a monotherapy for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a PI and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent.6 DARZALEX is the first monoclonal antibody (mAb) to receive U.S. Food and Drug Administration (FDA) approval to treat multiple myeloma. DARZALEX is indicated in Europe in combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant;  for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy; and as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a PI and an immunomodulatory agent and who have demonstrated disease progression on the last therapy. In Japan, DARZALEX is approved in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for treatment of adults with relapsed or refractory multiple myeloma.  DARZALEX is the first human CD38 monoclonal antibody to reach the market.  For more information, visit www.DARZALEX.com.

Daratumumab is a human IgG1k monoclonal antibody (mAb) that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells.  Daratumumab triggers a person’s own immune system to attack the cancer cells, resulting in rapid tumor cell death through multiple immune-mediated mechanisms of action and through immunomodulatory effects, in addition to direct tumor cell death, via apoptosis (programmed cell death).6,7,8,9,10,

Daratumumab is being developed by Janssen Biotech, Inc. under an exclusive worldwide license to develop, manufacture and commercialize daratumumab from Genmab. A comprehensive clinical development program for daratumumab is ongoing, including multiple Phase III studies in smoldering, relapsed and frontline multiple myeloma settings and in amyloidosis.  Additional studies are ongoing or planned to assess the potential of daratumumab in other malignant and pre-malignant diseases, such as NKT-cell lymphoma, myelodysplastic syndromes, B and T-ALL.  Daratumumab has received two Breakthrough Therapy Designations from the U.S. FDA, for multiple myeloma, as both a monotherapy and in combination with other therapies.

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications.  Daratumumab is in clinical development for additional multiple myeloma indications and other blood cancers.  A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis.  Genmab also has a broad clinical and pre-clinical product pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies and the HexElect™ platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products.  Genmab has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com.


Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications

T: +45 33 44 77 20; E: rcg@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody™; HexElect™; and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Pharmaceutica NV.

1 American Cancer Society. "Multiple Myeloma Overview." Available at https://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-what-is-multiple-myeloma.Accessed June 2016.

2  Cancer Information Service. “Projected Cancer Statistics 2017.” Available at https://ganjoho.jp/en/public/statistics/short_pred.html. Accessed February 2018..

3  GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide: Number of New Cancers in 2015. Available at: https://globocan.iarc.fr/old/burden.asp?selection_pop=224900&Text-p=World&selection_cancer=17270&Text-c=Multiple+myeloma&pYear=3&type=0&window=1&submit=%C2%A0Execute. Accessed June 2016.

4  American Cancer Society. "How is Multiple Myeloma Diagnosed?" https://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-diagnosis. Accessed June 2016.

5  Kumar, SK et al. Risk of progression and survival in multiple myeloma relapsing after last therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012; 26:149-57.

6 DARZALEX Prescribing information, May 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761036s013lbl.pdfLast accessed May 2018

7 De Weers, M et al. Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors. The Journal of Immunology. 2011; 186: 1840-1848.

8 Overdijk, MB, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015; 7: 311-21.

9 Krejcik, MD et al. Daratumumab Depletes CD38+ Immune-regulatory Cells, Promotes T-cell Expansion, and Skews T-cell Repertoire in Multiple Myeloma. Blood. 2016; 128: 384-94.

10 Jansen, JH  et al. Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via Fc receptor-mediated crosslinking. Blood. 2012; 120(21): abstract 2974.

Company Announcement no. 36

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Genmab A/S

Kalvebod Brygge 43

1560 Copenhagen V




Relateret indhold
22 mar - 
Genmab-partner søger om udvidet brug af Darzalex i Euro..
20 mar - 
Onsdagens aktier: FLSmidth med til at stoppe langvarig ..
20 mar - 
Aktier/middag: Udenlandske investorer får FLSmidth til ..
Relateret debat
25 mar - 
Den har jo holdt sig flot idag, ifht. næsten alle..
25 mar - 
Det kan kun guderne vide, men vi kan da håbe. 🤔
25 mar - 
Hej transalp, tak for link!👍 Og mon ikke kursen snart ..

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
22 mar
Har aktien:   GENMAB: PARTNER SØGER OM UDVIDET BRUG AF DARZALEX I EUROPA 12:05Genmabs amerikanske pa..
20 mar
  Pengkom!  Det er et sådannne indlæg, som ødelægger en saglig debat. Jeg syntes det er pineligt, at..
22 mar
En godkendelse i USA er lige om hjørnet. Der er KÆMPE chance for en godkendelse - dette ved vi efter..
20 mar
Der er kommet recepttal for februar og Venetoclax i problemer i MM, så formodentlig det der løfter a..
25 mar
22 mar
Den må da snart fise over de 1200, med den og de nu begge snarlige godkendelser!
22 mar
Vil skyde på vi lukker i 1162.
20 mar
Den burde være i min 1500 kr nu, men det kommer bare på en voldsom måde når det sker. Har Genmab og ..
20 mar
Tre kandidater:   Zymeworks (primært bispecifikke antistofs baseret med god platform - middel risiko..
22 mar
Mon ikke vi allerede idag skal lukke i pænt plus!   God weekend!

Middag: B&O styrtdykker – Novo styrker C25

26-03-2019 11:37:07
Mens aktien i Bang & Olufsen styrtdykker efter en nedjustering, sørger en pæn stigning i Novo Nordisk-aktien for, at det danske C25-indeks distancerer sig fra sine toneangivende europæiske indeks-kolleger.Det danske eliteindeks stiger tirsdag middag 0,8 pct. til 1121,15 kr., og samtidig ligger det brede fælleseuropæiske Stoxx 600-indeks 0,4 pct. højere. Novos bidrag til den danske fremdrift er et ..

Euroinvestor spørger: Skal boligpriserne op eller ned?

Relaterede nyheder
26-03-2019 08:45:19
Skal boligpriserne op eller ned i dit lokalområde indenfor de næste 12 måneder - og hvad med ledigheden?Det er nogle af de spørgsmål, vi stiller i vores månedlige PrivatInvestorUndersøgelse (PIU), hvor vi også spørger om dine forventninger til aktiemarkederne og økonomien.//Euroinvestor

USA børsluk: Boeing til tops – Apple falder på konference-dag

25-03-2019 21:18:02
Markederne i USA lukkede fladt. DOW JONESDow Jones-indekset lukkede med en ændring på et rundt 0. Dagens tre mest stigende aktier i Dow:  Boeing oppe med 2,3 pct. Caterpillar Inc. oppe med 1,2 pct. Verizon oppe med 0,5 pct. De tre aktier der faldt mest i Dow:  Apple Inc. nede med 1,2 pct. DowDuPont nede med 1,2 pct. Walgreens Boot Alliance nede med 1,2 pct. S&P500 S&P500-indekset lukkede ligeledes..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
Mandagens aktier: Ambu ned og Pandora op på dag med recessionsfrygt
USA åbning – Boeing, Apple & McDonalds
Morgen: B&O i massivt fald efter ny nedjustering
Zealand Pharma/Nordea: Hæver kursmålet og gentager "køb"
Hård kritik af arbejdsmiljø på Vestas-fabrik

Relaterede aktiekurser

Genmab A/S 1.164,50 1,4% Stigning i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
26. marts 2019 13:13:58
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190320.1 - EUROWEB6 - 2019-03-26 13:13:58 - 2019-03-26 13:13:58 - 1 - Website: OKAY